Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of brexpiprazole for agitation associated with Alzheimer's dementia
2017-003940-19Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Brexpiprazole with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in CMAI total score. Started May 2018; status: completed.
02
Drugs
brexpiprazole
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2017-003940-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003940-19.